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The polymerase chain reaction was used to detect genomic sequences of the positive-stranded RNA of bovine
viral diarrhea virus (BVDV), a member of the family Togaviridae. Using a set of 20-bp primers located within
the conserved 3' region of the BVDV genome, we were able to consistently amplify a 205-bp target sequence
from BVDV cDNA. BVDV RNAs from cell culture-propagated BVDV reference strains, diverse unrelated
cytopathic and noncytopathic field isolates, and clinical serum samples were transcribed to cDNA by using
avian myeloblastosis virus reverse transcriptase and further specifically amplified by using the polymerase
chain reaction assay. The amplification assay was sensitive enough to detect one molecule of cloned BVDV
cDNA. Reconstitution experiments conducted by adding decreasing amounts of BVDV (NADL strain) to
BVDV-free serum indicated that the threshold of sensitivity of the assay was l1 50% tissue culture infective
dose. These results show that the polymerase chain reaction may be used for the rapid detection of diverse
strains of BVDV in cell cultures, biological products, and clinical specimens from cattle.
Bovine viral diarrhea virus (BVDV) is one of the most
important pathogens of the bovine fetus (3). BVDV infection
inflicts insidious and sometimes devastating losses on both
beef and dairy cattle industries as a result of reproductive
and respiratory disease (11). The virus has a genome com-
posed of single-stranded (positive-polarity) nonpolyadeny-
lated RNA of about 12.5 kb in length (6). Field BVDV
isolates can be divided into two biotypes according to their
ability to produce cytopathic effect in cell cultures (24).
Infection with the noncytopathic biotype during the first
trimester of gestation leads to abortions, stillbirths, or the
birth of persistently infected (PI), immunologically tolerant
calves. Generally, the PI animal is apparently healthy, but if
superinfection with a cytopathic biotype takes place, the
animal usually dies of mucosal disease (1, 2). The percentage
of PI cattle in individual herds is usually small; however, it is
enough to allow transmission of the infection to other cattle,
thus perpetuating BVDV in the herd (1). In order to control
the disease, it is important to unequivocally identify and
remove PI animals from cattle herds. Furthermore, the
presence of BVDV in fetal serum and other bovine products
used for cell culture poses a great problem for research
laboratories and biological industries. BVDV is one of the
leading contaminants of cell cultures and veterinary biologic
products (14, 18). The techniques currently in use to detect
and/or isolate BVDV in contaminated cell cultures as well as
in clinical samples obtained from acutely infected and PI
animals are immunofluorescence and/or virus isolation in
cell cultures. These techniques are time-consuming and do
not provide rapid diagnostic results (8, 19). In this paper, we
describe a rapid and sensitive method for detection ofBVDV
by using the polymerase chain reaction (PCR) assay (21).
MATERIALS AND METHODS
Cells. A mycoplasma- and BVDV-free diploid line of
bovine turbinate (BT) cells was obtained from R. Van
* Corresponding author.
t Publication no. 9169 of IANR (University of Nebraska).
Deusen (National Veterinary Services Laboratories, U.S.
Department of Agriculture, Ames, Iowa).
Reference strains. Singer and NADL strains of BVDV
were obtained from the American Type Culture Collection,
and Oregon and New York strains were obtained from the
National Veterinary Services Laboratories (Diagnostic Vi-
rology).
BVDV isolates. BVDV samples were isolated in primary
bovine testicle cell cultures from clinical samples obtained
from animals with mucosal disease in New York State.
These isolates were confirmed to be serologically unrelated
by monoclonal antibody typing (unpublished results). The
presence of BVDV was confirmed after serial passages (n 2
3) by direct immunofluorescence with a BVDV-specific
conjugate supplied by the National Veterinary Services
Laboratories. These samples included four isolates of the
cytopathic biotype obtained from buffy coat (sample 7) and
oral swabs (samples 9, 10, and 11) as well as two isolates of
the noncytopathic biotype obtained from buffy coat (sample
6) and oral swabs (sample 8).
Clinical samples. Sera submitted to the Veterinary Diag-
nostic Center of the University of Nebraska from BVDV-
viremic animals with clinical cases of mucosal and respira-
tory disease were obtained.
Infectious-serum reconstitution. To assess the sensitivity of
the amplification test, BVDV strain NADL was added in
serial (10-fold) dilutions to BVDV-free fetal bovine serum.
BVDV cDNA. A 2,160-bp cDNA flanked by PstI restric-
tion sites cloned in pBR322 plasmid (pBV-KPB) was ob-
tained from Marc Collett (Molecular Genetics, Inc., Min-
netonka, Minn.). This cDNA corresponds to the sequences
between bases 9835 and 12225 of the NADL strain genome.
RNA extraction from cell cultures. Approximately 107 BT
cells grown in minimal essential medium supplemented with
10% horse serum were infected at a multiplicity of infection
of 0.2 to 1, and 48 h later cytoplasmic RNA was extracted
(10). Briefly, after two washes with cold phosphate-buffered
saline, the cell pellet was lysed with 0.5% Nonidet P-40,
digested for 15 min at 37°C with proteinase K (200 ,ug/ml)-
sodium dodecyl sulfate (SDS) (0.2% [wt/vol]), and then
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from the resulting supernatant with phenol-chloroform. The
RNA was precipitated with cold 100% ethanol in the pres-
ence of 3 M ammonium acetate, pH 5.2, on dry ice for 1 h.
The pellet was dried in a desiccator and resuspended in
water.
RNA extracted from serum samples. A 100-pul volume of
serum was added to 450 pJ of STE buffer (100 mM NaCl, 50
mM Tris, 5 mM EDTA; pH 8), and digestion was carried out
for 10 min at room temperature with proteinase K (200
ptg/ml) and for 20 min at 56°C in the presence of SDS (0.1%
[wt/vol]). After two extractions with phenol-chloroform, the
RNA fraction was precipitated for 1 h on dry ice, resus-
pended in 10 p1 of distilled water, and submitted for cDNA
production by reverse transcription (RT).
Transcription of RNA to cDNA. After different denatur-
ation procedures addressed to preventing or minimizing
secondary structure formation were tried (6, 15), the follow-
ing procedure was selected. A 10-pl volume of RNA was
added to 1.5,ul of primer 2.2 (40,umol), and the solution was
heated at 70°C for 5 min and then chilled on ice. For the RT
assay, denatured RNA was incubated at 42°C for 2 h in the
presence of Schimke solution (10 mM dithiothreitol, 10 mM
MgCl2, 70 mM KCl, 80 mM Tris; pH 8), deoxynucleoside
triphosphates (7.5,uM; Pharmacia), 1 plI of RNasin (28 U/,u;
Promega), and 1 pl of avian myeloblastosis virus reverse
transcriptase (19.6 U/ml; Life Sciences). A 5-pul portion of
this solution was used for the PCR assay.
Primers for PCR and target fragment. The 20-bp primers
2.1 and 2.2 used for amplification of BVDV have a GC
content of 35% and overall free energy coefficients for
formation of secondary structure of 0.7 and -1, respectively
(CGC program, University of Wisconsin). The primers were
synthesized (Genetic Designs, Inc., Houston, Tex.) and
purified by electrophoresis in polyacrylamide. The 205-bp
target has an overall free energy for secondary structure
formation of -24.9 and is located between bases 9893 and
10098 (6). There is a single recognition site for the restriction
enzyme BstEII at base 9964 (see Fig. 1).
PCR. Optimization was carried out by varying (i) the
concentrations of MgCl2 in the reaction buffer, (ii) the
annealing temperatures, and (iii) the number of cycles.
Briefly, the optimized protocol is as follows. A 10-pd volume
of lOx buffer (15 mM MgCl2, 400 mM Tris-HCl, 500 mM
KCl, 1% gelatin), 16 ,ul of an equimolar mixture of deoxy-
nucleoside triphosphates (5 mM), 3 RI of each primer (40
,umol), and 5 pul of cDNA template were added in a total
volume of 100 p1. For amplification of cDNA obtained by
previous RT of BVDV RNA, 2.5 pul of primer 2.2 was added.
The mixture was heated at 95°C for 5 min, after which 3 U of
Taq polymerase (Perkin-Elmer Cetus) in a 5-p[l volume of 1x
buffer was added. A layer of 50 pl1 of Nujol mineral oil
(Perkin-Elmer) was added to prevent evaporation of the
reagents. The reaction consisted of 40 equal cycles on an
automated thermal cycler (Perkin-Elmer Cetus). Each cycle
was composed of 1 min at 95°C (denaturation step), 1 min at
55°C (primer-annealing step), and 2 min at 72°C (primer
extension step). Controls used in each amplification round
included (i) plasmid pBR322, (ii) RNA from uninfected BT
cells, (iii) RNA extracted from BVDV-free bovine fetal
serum, and'(iv) a replicate sample including a mixture of all
reagents with no template added.
Analysis of PCR-amplified products. (i) Electrophoresis. A
10-,ul sample of each amplified product was run in 2%
NuSieve agarose in Tris-borate-EDTA buffer at 70 V for 2 h.
(ii) Control of amplification specificity. The 205-bp amplifi-
cation fragment has a restriction site for BstEII that pro-













FIG. 1. Illustration of the 205-bp amplification target from
BVDV cDNA. Restriction enzyme BstEII cuts the target into two
fragments, 71 and 134 bp long.
duces two sizeable fragments upon digestion (71 and 134 bp)
(Fig. 1). A 50-,u portion of each reaction mixture (half of the
total volume) was extracted with phenol-chloroform, precip-
itated with 100% ethanol-3 M ammonium acetate (pH 5.2),
and resuspended in 16 p1 of water. BstEII (8 U/pd; Bethesda
Research Laboratories) digestion was carried out as recom-
mended by the manufacturer. A sample of 10 pl1 of the
digested product was electrophoresed under the conditions
described above.
(iii) Southern blot. After electrophoresis, DNA in the gels
was blotted onto a nylon membrane (Hybond; Amersham)
and then denaturated and attached to the filter by exposure
to UV light (22).
(iv) Hybridization. A specific 30-bp probe overlapping the
BstEII site was constructed (Genetic Designs, Inc.). The
oligonucleotide was labeled at the 5' end with 32p. Briefly, 15
ng of probe (10 ng/plI) was mixed with 5 p1 of reaction buffer
(Tris [pH 7.4], 500 mM; MgCl2, 100 mM; dithiothreitol, 50
mM; spermidine, 10 mM), 1 p1 of polynucleotide kinase T4
(10 U/pul; Biolabs), and 10 p1 of [y-32P]ATP (10 mCi/ml;
Amersham) in a total volume of 50 p1, and the mixture was
incubated for 1 h (7). A total of 50 pl1 of STE buffer was
added to the mixture, and the mixture was passed through a
Sephadex G-50 column for 5 min at 2,000 x g. Prehybrid-
ization was conducted for 30 min at 55°C in 5 x SSPE-1 x BP
(2% bovine serum albumin, 2% polyvinylpyrrolidone)-1%
SDS, and hybridization was performed in the same buffer
containing at least 4 x 106 cpm of probe per ml for 1 h at
55°C. The filter was washed in 1% SSPE-1% SDS three
times for 5 min at room temperature and one time for 3 min
at 55°C. After the filter was dried, it was exposed at -70°C
to Kodak film (XAR 5) and developed and/or submitted for
detection in a radioanalytic imaging system (AMBIS Sys-
tems, Inc.). As a negative control for hybridization, a 217-bp
fragment from the pseudorabies virus gp5O gene was used.
RESULTS
Suitability of primers for amplification of cloned BVDV
cDNA. The set of primers that consistently amplifies the
sequence target within pBV-KPB is shown in Fig. 1. The
specificity of the reaction was demonstrated by the size of
the amplification product which corresponds to the predicted
205-bp fragment (Fig. 1). Specific cleavage by the restriction
enzyme BstEII yielded a pair of segments of predictable
sizes (71 and 134 bp), which hybridized specifically with the
VOL. 29, 1991






FIG. 2. (a) Agarose gel electrophoresis of the 205-bp amplified
fragment before (lane A) and after (lane C) digestion with BstEII.
Lane B, HaeIII-digested fragments from phage 4X174. Arrows
indicate the 205-, 134-, and 71-bp fragments. Amplified products not
evident in the figure were visible in the original gel. (b) Southern blot
of the gel hybridized with a 30-bp internal probe after a 2-h
exposure.
customized internal probe (Fig. 2). By using an optimized
protocol for amplification (see Materials and Methods), it
was possible to detect 70 x 10-18 g of plasmid template by
visualization of the amplification product after electrophore-
sis in an ethidium bromide agarose gel (Fig. 3a, lane C).
When the blotted amplification products were hybridized




FIG. 3. (a) Agarose gel electrophoresis of PCR products, using
decreasing dilutions of template plasmid pBV-KPB. Lanes: A, B, C,
D, and E, 7, 0.7, 0.07, 0.007, and 0.0007 fg of pBV-KPB, respec-
tively; F, HaeIII-digested fragments from phage 4X174; G, 217-bp
amplification fragment from pseudorabies virus gpSO gene. (b)
Southern blot of the gel hybridized with a 30-bp internal probe after
a 20-h exposure.
FIG. 4. (a) Agarose gel electrophoresis of PCR products, with
cell-propagated reference strains and spiked BVDV strain NADL
serum used as targets for amplification. Lanes: A, uninfected BT
cell RNA; B through E, BT cells infected with NADL, Oregon,
Singer, and New York reference strains, respectively; H, HaeIII-
digested fragments from phage 4X174; G through L, BVDV-free
fetal calf serum reconstituted with 10,000, 1,000, 100, 10, 1, and 0.1
TCID50 of BVDV strain NADL per 100 ,ul. Arrowhead indicates the
205-bp fragment. (b) Southern blot of the gel hybridized with a 30-bp
internal probe scanned for 15 min with a radioanalytical image
system.
l0-18 g of cDNA (Fig. 3b, lane D). These quantities corre-
spond to approximately 10 molecules and 1 molecule of
insert, respectively. As a negative control, we used plasmid
pBR322. Using 1 ,ug of this plasmid, we consistently failed to
produce amplification (data not shown).
Coupling of BVDV cDNA amplification with BVDV RNA
RT. Figure 4, lane B, shows the results of a typical experi-
ment to amplify cDNA prepared by RT of cytoplasmic RNA
from BT cells infected with the NADL strain of BVDV. No
amplification was detected with RNA extracted from unin-
fected BT cells (Fig. 4, lane A).
The suitability of the test for direct detection of BVDV in
serum was initially assessed by using BVDV-free serum that
was artificially infected by the addition of 10i 50% tissue
culture infectious doses (TCID50) of BVDV strain NADL
per ml. Also in this case, a positive signal was obtained (data
not shown). To further assess the sensitivity, we conducted
reconstitution experiments by adding known decreasing
amounts (10-fold dilutions) of BVDV (NADL strain) to
replicate aliquots of BVDV-free bovine serum. These sam-
ples were used for the RT plus PCR reaction. The results of
this assay are shown in Fig. 4. Upon Southern blotting of the
amplified products and hybridization with the internal probe,
the threshold of sensitivity of our test in BVDV-infected
serum was .1 TCID5J100 pI of serum (Fig. 4). The BVDV
titer of each dilution of reconstituted infectious serum was
confirmed by endpoint titration. The amplification products
obtained after RT plus PCR of RNAs fulfilled the requisites
for specificity as described above.
Ability of the coupled BVDV RT and PCR tests to detect
reference strains and isolates of BVDV. The optimized proto-
col was used successfully to amplify cDNAs transcribed
from RNA fractions obtained from BT cells infected with
reference strains Singer, Oregon, and NADL (all cytopathic
biotypes) and New York (a noncytopathic biotype) (Fig. 4,
J. CLIN. MICROBIOL.
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TABLE 1. Classification of samples used for BVDV PCR
RNA PCR ViralIsolate Origina source Biotype result assaysource
~~~~~~~~result
NADL ATCC CCPb Cytopathic + NDc
Oregon NVSL CCP Cytopathic + ND
Singer NVSL CCP Cytopathic + ND
New York ATCC CCP Noncytopathic + ND
7 B.c.d CCP Cytopathic + ND
9 O.s.d CCP Cytopathic + ND
10 O.s.d CCP Cytopathic + ND
11 O.s.d CCP Cytopathic + ND
6 B.c.d CCP Noncytopathic + ND
8 O.s.d CCP Noncytopathic + ND
57 Serum Serum Noncytopathic - ND
57e Serum CCP Noncytopathic + +
77 Serum Serum Noncytopathic + +
94 Serum Serum Noncytopathic + +
87 Serum Serum Cytopathic + +
14 Serum Serum Noncytopathic
a ATCC, American Type Culture Collection; NVSL, National Veterinary
Services Laboratories; B.c., buffy coat; O.s., oral swab. Serum, Clinical
samples from herds with history of persistent BVDV infection. The samples
represent different Nebraska counties encompassing a wide area.
b CCp, Cell culture passage.
c ND, Not done.
d Isolates from New York.
e First passage in cell culture.
lanes A through F, and Table 1). In addition, this test was
effective in detecting four cytopathic and two noncytopathic
unrelated isolates propagated in cell cultures (Table 1).
We also tested six unrelated serum samples with a previ-
ous record of positive virus isolation which had been stored
at -70°C for an extended period of time. As a positive
control, we used reconstituted infectious serum (by addition
ofNADL strain, 103 TCID50 per ml). In four of six samples,
positive amplification products were obtained directly from
the serum material (Table 1). In one of the negative cases,
although no virus was detected in the original serum mate-
rial, positive amplification was achieved when the test was
performed on supernatant of the first blind passage of this
sample in cell culture, which also had been preserved at
-70°C (Table 1). The other sample remained negative by
PCR and also by viral isolation throughout a total of three
blind passages. The amplification products fulfilled the cri-
teria for specificity described above. No amplification was
observed with cDNA (reverse-transcribed RNA) from unin-
fected BT cells, from BVDV-free bovine fetal serum, or
from serum from a BVDV-free calf.
DISCUSSION
From our results, it is evident that it is feasible to
specifically amplify RNA sequences of BVDV by coupling
the BVDV reverse transcriptase reaction and BVDV cDNA
amplification. In addition, the set of primers selected was
suitable for amplification of RNA from a wide range of
BVDV isolates obtained either after serial propagation of the
isolates in cell cultures or directly from clinical samples.
Since the primers are used both in the production of
specific cDNA and in the amplification of that cDNA by
PCR, the design of such sequences is of fundamental impor-
tance for the preparation of a protocol to amplify RNA
targets. We originally selected several sets of 20-bp primers
mapping to the conserved region of the BVDV genome
which is close to the 3' end. We based this selection on
genomic areas of high homology between two published
sequences of the BVDV genome (6, 16). At the same time,
we selected the primers because of their relatively low GC
content and their acceptable free energy coefficient (i.e., a
free energy coefficient that is positive or near zero, which
indicates a low probability of secondary structure forma-
tion). Of the two sets of primers that we tested under
different conditions of amplification, only one (herein re-
ported) specifically amplified BVDV RNA. The 205-bp tar-
get for amplification is included in the region that codes for
the putative precursor of the RNA polymerase (5). This also
suggests that our target sequence lies within a highly con-
served area of the BVDV genome. This high level of
conservation is a desirable feature for a primer-target se-
quence selected for diagnostic purposes, because it contrib-
utes directly to detection of a wide range of diverse virus
strains. Using the set of primers described above, we were
able to detect 15 diverse isolates of both BVDV biotypes.
This is particularly important when considering the reported
difficulties in finding a universal synthetic oligonucleotide
sequence which would be able to recognize RNAs from
different BVDV isolates by means of filter hybridization (17).
Our results may reflect the fair number of mismatches that
PCR tolerates (23). However, the specificity is still high, as
evidenced by the absence of nonspecific amplification.
We failed to detect BVDV-specific amplification in two
clinical serum samples. However, we could detect the virus
by amplification in the supernatant of the first passage of one
of these samples in cultured cells. Although the failure to
directly detect BVDV in one serum sample apparently
challenges the sensitivity of our test, other factors should be
taken into account, such as the fact that hemoglobin was
observed in both negative serum samples. Compounds de-
rived from heme (porphyrins) have been reported to be
inhibitors of PCR (13).
Although intensive, the coupled protocol for RT plus PCR
provides a rapid diagnosis of BVDV. In all cases, results
were obtained within 24 to 36 h. This is significantly less time
than the minimal time required to obtain results by using
standard viral isolation techniques.
Since its development, the PCR has been used for the
detection of several RNA viruses, such as human immuno-
deficiency virus (12), rubella virus (4), enterovirus (20),
rhinovirus (9), and hepatitis delta virus (25). Our results
show that this technique should be useful for the diagnosis of
BVDV in cell lines, bovine serum, and tissues because of its
sensitivity and rapid performance.
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